Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.
|Videos|June 24, 2021
The Conversation About Nutrition: Stressing Brain Health, Not Weight Loss
Author(s)Teralyn Sell, PhD, MS, NCC, LPC
Are you having the conversation about food with your patients?
Advertisement
Teralyn Sell, PhD, MS, NCC, LPC, talks about leading the conversation away from weight loss and towards improving brain health when discussing nutrition.
For more on food improving care, see
Dr Sell holds a doctorate in psychology and is the founder of Pro Recovery Rx, a supplement line dedicated to supporting brain health for individuals in addiction recovery. She also teaches a class called NeuroHealth Coach, which helps professionals integrate brain health into their daily lives.
Advertisement
Related to this article
An endocrinologist warns psychiatrists against overreading peripheral thyroid hormones and flags kelp and T3 microdosing as underrecognized risks.
Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
2
Dosing MDD Therapies in Medically Complex Patients: Metabolism and Interactions
3
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
4
Choosing an Antidepressant: Art, Science, and Knowing Your Patient
5